Characterization of a Rat Model of Moderate Chronic Renal Failure—Focus on Hematological, Biochemical, and Cardio-Renal Profiles

REFERENCES

• Parmar MS. Chronic renal disease. BMJ. 2002;325:85–90.
   PubMed Web of Science ®Google Scholar
• Kerr PG. Renal anemia: Recent developments, innovative approaches and future directions for improved management. Nephrology (Carlton). 2006;11:542–548.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P. Anaemia and inflammation: What are the implications for the nephrologists? Nephrol Dial Transplant. 2003;18:viii17–viii22.
   PubMedGoogle Scholar
• Costa E, Pereira BJ, Rocha-Pereira P, . Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol. 2008;28:677–683.
   PubMed Web of Science ®Google Scholar
• Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: A wake-up call. J Am Soc Nephrol. 2004;15:524–537.
   PubMed Web of Science ®Google Scholar
• Bakris GL. Protecting renal function in the hypertensive patient: Clinical guidelines. Am J Hypertens. 2005;18:112S–119S.
   Web of Science ®Google Scholar
• Liu ZC, Chow KM, Chang TM. Evaluation of two protocols of uremic rat model: Partial nephrectomy and infarction. Ren Fail. 2003;25:935–943.
   PubMed Web of Science ®Google Scholar
• Ofstad J, Horvei G, Kvam FI, . Glomerular hemodynamics in progressive renal disease. Kidney Int. 1992;36:S8–S14.
   Google Scholar
• Fine L. The biology of renal hypertrophy. Kidney Int. 1986;29:619–634.
   PubMed Web of Science ®Google Scholar
• Gretz N, Waldherr R, Strauch M. The remnant kidney model. In: Gretz N, Strauch M ( eds.). Experimental and genetic rat models of chronic renal failure. Basel: Karger; 1993:1–28.
   Google Scholar
• Hostetter TH, Olson JL, Rennke HG, . Hyperfiltration in remnants nephrons: A potentially adverse response to renal ablation. J Am Soc Nephrol. 2001;12:1315–1325.
   PubMed Web of Science ®Google Scholar
• Toblli JE, Cao G, Rivas C, Kulaksiz H. Heart and iron deficiency anaemia in rats with renal insufficiency: The role of hepcidin. Nephrology (Carlton). 2008;13:636–645.
   PubMedGoogle Scholar
• Reis F, Rocha L, Ponte L, . Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. Life Sci. 2005;77:2514–2528.
   PubMedGoogle Scholar
• Estepa V, Ródenas S, Martín MC. Optimización de un método para la determinación de la peroxidación lipídica en suero humano. Anal Real Acad Farm. 2001;67:1–17.
   Google Scholar
• Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: The FRAP assay. Anal Biochem. 1996;239:70–76.
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: Renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002;136:604–615.
   PubMed Web of Science ®Google Scholar
• Schnaper HW, Jandeska S, Runyan CE, Hubchak SC, Basu RK, Curley JF, Smith RD, Hayashida T. TGF-beta signal transduction in chronic kidney disease. Front. Biosci. 2009;14: 2448–2465.
   Web of Science ®Google Scholar
• Hörl WH. Iron therapy for renal anemia: How much needed, how much harmful? Pediatr Nephrol. 2007;22:480–489.
   PubMedGoogle Scholar
• Brugnara C. Iron deficiency and erythropoiesis: New diagnostic approaches. Clin Chem. 2003;49:1573–1578.
   PubMed Web of Science ®Google Scholar
• Oschry Y, Eisenberg S. Rat plasma lipoproteins: Re-evaluation of a lipoprotein system in an animal devoid of cholesteryl ester transfer activity. J Lipid Res. 1982;23:1099–1106.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: An approach to pathogenesis and treatment. Am J Nephrol. 2008;28:958–973.
   PubMedGoogle Scholar
• Johnson DW, Armstrong K, Campbell SB, . Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton). 2007;12:391–398.
   PubMed Web of Science ®Google Scholar
• Chan CM. Hyperlipidemia in chronic renal disease. Ann Acad Med Singapore. 2005;35:31–35.
   Google Scholar
• Silverberg D, Wexler D, Blum M, . The cardio-renal anaemia syndrome: Does it exist? Nephrol Dial Transplant. 2003;18:viii7–viii12.
   PubMedGoogle Scholar
• Wexler D, Silverberg D, Blum M, . Anaemia as a contributor to morbidity and mortality in congestive heart failure. Nephrol Dial Transplant. 2005;20:vii11–vii15.
   PubMedGoogle Scholar
• Ritz E, Koomans HA. New insights into mechanisms of blood pressure regulation in patients with uremia. Nephrol Dial Transplant. 1996;11:52–59.
   PubMedGoogle Scholar
• Campese VM. Neurogenic factors and hypertension in chronic renal failure. J Nephrol. 1997;10:184–187.
   PubMed Web of Science ®Google Scholar
• Malyszko J, Malyszko JS, Pawlak D, . Homeostasis, platelet function and serotonin in acute and chronic renal failure. Thromb Res. 1996;83:351–361.
   PubMedGoogle Scholar
• Hojs R, Hojs-Fabjan T, Balon BP. Atherosclerosis in patients with end-stage renal failure prior to initiation of hemodialysis. Ren Fail. 2003;25:247–254.
   PubMed Web of Science ®Google Scholar
• Martín-Mateo MC, Sánchez-Portugal M, Iglesias S, de Paula A, Bustamante J. Oxidative stress in chronic renal failure. Ren Fail. 1999;21:155–167.
   PubMed Web of Science ®Google Scholar
• Manning RD Jr, Tian N, Meng S. Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol. 2005;25: 311–317.
   PubMed Web of Science ®Google Scholar